Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 13   

Articles published

NYMX 4.95 -0.04 (-0.80%)
price chart
Pharma Stocks to Watch: BSD Medical Inc. (NASDAQ:BSDM), Nymox ...
BSD Medical Inc. (NASDAQ:BSDM) which provides systems that use heat therapy to treat cancer, said it has begun a Phase I/II study using hyperthermia, delivered using either the BSD-2000 Hyperthermia System or the BSD-500 Hyperthermia System, ...
Related articles »  
Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate ...
Related articles »  
Nymox Pharma (NYMX) Issues Positive Update on US Study NX02-0022 Efficacy
Nymox Pharma (Nasdaq: NYMX) announces new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH.
Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial ...  Wall Street Journal
Related articles »  
Top Stories - Caterpillar (NYSE:CAT), General Electric (NYSE:GE) , Casella ...
Nymox Pharma Corporation (NASDAQ:NYMX) announces new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH.
Hot Watch List: QUALCOMM, Inc. (NASDAQ:QCOM), Alcatel Lucent SA (ADR ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced on 15 July the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate ...
Trader's Recap - Oi SA (ADR) (NYSE:OIBR), Gogo Inc (NASDAQ:GOGO), TCF ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate (benign ...
Related articles »  
Active Biotech Stocks: AcelRx Pharmaceuticals (ACRX) & Nymox ...
Nymox Pharmaceuticals (NYMX) has a market cap of approximately $163 million and has had very good results to date on its NX-1207 drug for benign prostastic hyperplasia (BPH).